These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38940215)

  • 1. Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease.
    Arto C; Rusu EC; Clavero-Mestres H; Barrientos-Riosalido A; Bertran L; Mahmoudian R; Aguilar C; Riesco D; Chicote JU; Parada D; Martínez S; Sabench F; Richart C; Auguet T
    Eur J Clin Invest; 2024 Nov; 54(11):e14279. PubMed ID: 38940215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan Metabolism Is Associated with BMI and Adipose Tissue Mass and Linked to Metabolic Disease in Pediatric Obesity.
    Lischka J; Schanzer A; Baumgartner M; de Gier C; Greber-Platzer S; Zeyda M
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
    Song P; Ramprasath T; Wang H; Zou MH
    Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.
    Engin AB; Engin A
    Adv Exp Med Biol; 2024; 1460():629-655. PubMed ID: 39287867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.
    Jovanovic F; Candido KD; Knezevic NN
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system.
    Ala M
    Int Rev Immunol; 2022; 41(3):326-345. PubMed ID: 34289794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat.
    Wang J; Li X; He S; Hu L; Guo J; Huang X; Hu J; Qi Y; Chen B; Shang D; Wen Y
    J Ethnopharmacol; 2018 Mar; 214():13-21. PubMed ID: 29217494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease.
    Whiley L; Chappell KE; D'Hondt E; Lewis MR; Jiménez B; Snowden SG; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Swann JR; Hye A; Lovestone S; Legido-Quigley C; Holmes E;
    Alzheimers Res Ther; 2021 Jan; 13(1):20. PubMed ID: 33422142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
    Boros FA; Bohár Z; Vécsei L
    Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of microbial and indoleamine-2,3-dioxygenase-derived tryptophan metabolites with immune activation in healthy adults.
    Riazati N; Kable ME; Newman JW; Adkins Y; Freytag T; Jiang X; Stephensen CB
    Front Immunol; 2022; 13():917966. PubMed ID: 36248784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic immune activation underlies morbid obesity: is IDO a key player?
    Brandacher G; Hoeller E; Fuchs D; Weiss HG
    Curr Drug Metab; 2007 Apr; 8(3):289-95. PubMed ID: 17430117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Methyl tryptophan, an indoleamine 2,3-dioxygenase inhibitor, attenuates cardiac and hepatic dysfunction in rats with biliary cirrhosis.
    Shayesteh S; Guillemin GJ; Rashidian A; Faghir-Ghanesefat H; Mani AR; Tavangar SM; Dehpour AR
    Eur J Pharmacol; 2021 Oct; 908():174309. PubMed ID: 34252442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.
    Maria NI; van Helden-Meeuwsen CG; Brkic Z; Paulissen SM; Steenwijk EC; Dalm VA; van Daele PL; Martin van Hagen P; Kroese FG; van Roon JA; Harkin A; Dik WA; Drexhage HA; Lubberts E; Versnel MA
    Arthritis Rheumatol; 2016 Jul; 68(7):1688-99. PubMed ID: 26866723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.
    Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Bustamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ
    Breast Cancer Res; 2020 Oct; 22(1):113. PubMed ID: 33109232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
    Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
    Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver tissue lipids in metabolic dysfunction-associated steatotic liver disease with diabetes and obesity.
    Sourianarayanane A; Brydges CR; McCullough AJ
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102402. PubMed ID: 38909684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
    Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
    FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma.
    Sordillo LA; Sordillo PP
    Anticancer Res; 2023 Dec; 43(12):5275-5282. PubMed ID: 38030171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.